How much does exosome therapy cost?
Exosome therapy is the new buzz in the regenerative medicine industry because of how it can repair and regenerate your cells and tissues.
Exosome therapy is safer compared to other cellular therapy because it’s a cell-free therapy with no risk of rejection.
Exosome therapy will be beneficial to you if you’re dealing with conditions such as sport injuries, tissue regeneration, hair loss, erectile dysfunction, chronic pain and so many other applications .
In this article, you’ll be learning the cost of exosome therapy and how you can benefit from exosome therapy.
How the cost of exosome therapy is determined
All cells produce exosomes, which are microvesicles that contain biochemical and genetic information.
Hence, the cost of an exosome product (used in exosome therapy) will depend on what type of cell line (raw tissue source) used to extract the exosomes.
The first factor to determine the cost of an exosome product depends on the quality of the tissue source.
The most commonly used tissue types are cord blood, amniotic fluid and mesenchymal cell cultures.
Exosomes derived from mesenchymal cell cultures are the most difficult to obtain but offer the greatest therapeutic potential.
How much does exosome therapy cost?
The average cost of exosome therapy is $4,900, but the price can be anything from $3,500 – $6,500.
It’s also important to note that the price depends on your specific needs and your treatment plan, as decided by the doctor.
The doctor will schedule a consultation with you to determine your personalized treatment plan.
The exosome therapy can either be given as an IV infusion or as localized injections, depending on the purpose of the therapy.
Exosomes are very useful to revitalize, rejuvenate, restore, and reduce inflammations in the body.
Here are some ways you can benefit from exosome therapy
Hair loss therapy: If you’re in the early stages of hair loss, with exosome therapy you can regenerate your hair whether you’re a man or woman. After exosome therapy, you’ll start seeing new hair growth in as little as two to three months with very significant results showing 6 months or 1 year later.
Chronic pain: In case you’re experiencing chronic pain due to degenerative conditions such as arthritis, exosomes can help to subdue the pain by regenerating the cells and helping the body work better.
Degenerative conditions: If you’re struggling with degenerative medical conditions such as osteoarthritis and musculoskeletal injuries, exosome therapy can help your body repair the damage done to your cells by these conditions, prevent them from getting better, and help you to feel better.
Skin therapy: exosome therapy can reduce inflammation in the skin by improving the strength and elasticity of the skin.
Anti-aging: if you would like to retain your youthful glow, exosome therapy can make you feel young again by rejuvenating your skin due to its ability to reverse the cells dying due to aging.
Where can you get exosome therapy?
Cellular hope institutes provide exosome therapy for patients looking for better outcomes for various conditions.
The exosomes used at Cellular Hope Institute are obtained from umbilical cord tissue that is discarded after a new birth , which means these Exosomes have not been exposed to any contaminating or toxic agent because our cells are as healthy as our body. This gives it a higher capacity to regenerate your cells and tissues.
- Published in Corporate News / Blog
Culture Expanded MSCs
Mesenchymal Stem Cells (MSCs) are the most commonly used cells in stem cell therapy and regenerative medicine, due to their high and multi-potency. Mesenchymal Stem Cells (MSCs) can be isolated from different tissues in the body.
In this article, you’ll be learning about culture-expanded MSCs, how MSCs can be expanded, The potency of MSCs and the type of cells they can differentiate into.
What are culture expanded Mesenchymal Stem cells?
Mesenchymal stem cells are high potent cells used for cellular therapy and isolated from different parts of the body. Mesenchymal stem cells can be used to improve the patient outcome in diseases and conditions such as autoimmune diseases, degenerative diseases, nerve damage, diabetes mellitus, bone problems etc.
For every patient, millions of mesenchymal stem cells are needed and the exact amount varies according to disease, route of administration, administration frequency, weight, and age of patient.
Mesenchymal stem cells are expanded in a culture media, on a large scale in order to obtain the required quantity of cells needed for cellular therapy.
Culture expanded MSCs: How does it work?
Expanding Mesenchymal stem cells in a media involves step by step process of isolation and expansion.
Mesenchymal Stem Cells Isolation
Mesenchymal stem cells can be isolated from different tissues in the human body such as adipose tissues, dental pulp, human bone marrow, umbilical cord tissue, umbilical cord blood, peripheral blood and synovium.
Mesenchymal stem cells are expanded in culture to increase their yield and amplify their desired functions and potency.
Although the population of Mesenchymal Stem Cells obtained will vary from donor to donor, here are some steps to follow:
· Acquire fresh tissue extracts in strictly aseptic conditions, to maintain purity.
· To remove any cell clusters, you have to filter the cell suspension with a 70-mm filter mesh
· Use a centrifuge to roll the cells for about 5 minutes at 500g
· Suspend the cells again the cells to measure the cell viability and yield using Trypan blue exclusion
· Use in T75 culture dishes to culture the cells in 10 mL of complete MSC medium at a density of 25 × 106 cells/mL. You can then go on to Incubate the plates at 37 °C with 5% CO2 in a humidified chamber without any interruption.
· When it’s past 3 h, remove the non-adherent cells that accumulate on the surface of the dish by changing the medium and replacing it with 10 mL fresh complete medium.
· After an additional 8 h of culture, add 10ml fresh complete medium as a replacement for the existing medium. You’ll have to repeat this step every 8 h for up to 72 h of initial culture.
· Cells can be frozen in MSC growth media plus 10% DMSO (D2650) at a density of 2X106 cells/vial.
Expansion of Mesenchymal Stem Cells in a culture media
Culture expanded mesenchymal cells undergo various stages from the preparation of the culture plate, thawing of Mesenchymal stem cells, and the actual expansion of Mesenchymal stem cells.
The reason behind the cultural expansion of Mesenchymal stem cells is to get them to differentiate into other cell types such as osteoblast, adipocyte, and mesenchymal stromal cells.
In preparation, to expand MSCs in a culture media, you need a culture ware. You can get one plastic or glassware plate and coat it with a sufficient amount of 0.1% gelatin. Don’t forget to aspirate the gelatin solution from the coated plate or flask before you use it.
The next step involves the thawing of the Mesenchymal stem cells, and here are a few steps for you to follow:
After the recommended culture medium and coated culture ware is ready and on standby, remove the vial of Mesenchymal Stem Cells from liquid nitrogen and incubate in a 37C water bath and pay close attention to it, until all the cells are completely thawed. The extent of completely thawed frozen cells and how fast, are what determines the cell viability.
Once the cells have thawed completely, take steps to avoid contamination by disinfecting the walls with 70% ethanol, before you proceed to the next step.
Place the cells in a hood, and carefully transfer the cells to a sterile tube with a pipette (1 or 2ml pipette), Do this in such a way to prevent bubbles.
Then, add drops of Mesenchymal Stem cell expansion medium that have been pre-warmed to 37C to the tube containing the Mesenchymal stem cells.
Be careful to take your time when adding the medium to avoid osmotic shock which could lead to decreased viability.
Proceed to mix the suspension slowly by pipetting up and down two times while avoiding any bubbles.
Place the tube in a centrifuge and centrifuge the tube at 300 x g for 2-3 minutes to roll the cells, and you should not vortex the cells.
After this, then decant as much of the supernatant as possible. These steps are necessary to remove residual cryopreservative (DMSO).
Suspend the cells in a total volume of 10 mL of Mesenchymal Stem Cell Expansion Medium again or any alternative of choice, pre-warmed to 37 °C, containing freshly added 8 ng/mL FGF-2 (F0291).
The next step involves placing the cell suspension onto a 10-cm tissue culture plate or a T75 tissue culture flask.
Maintain the cells in a humidified incubator at 37 °C with 5% CO2.
The next day, exchange the medium with fresh Mesenchymal Stem Cell Expansion Medium (pre-warmed to 37 °C) containing 8 ng/mL FGF-2*. Replace with fresh medium containing FGF-2 every two to three days thereafter.
Isolate the cells when they are approximately 80% confluent, using Trypsin-EDTA and passaged further or frozen for later use.
Expansion of Mesenchymal Stem Cells
Once the cells are actively proliferating and have reached a confluence of approximately 80% (before 100%), you should subculture the cells.
Then remove the medium from the 10-cm tissue culture plate containing the confluent layer of human mesenchymal stem cells, carefully and apply 3-5 mL of Trypsin-EDTA Solution, before proceeding to incubate in a 37 °C incubator for 3-5 minutes.
Crosscheck the culture to see if all the cells are completely detached. Then, add 5 mL Mesenchymal Stem Cell Expansion Medium to the plate.
Swirl the plate mildly to mix the cell suspension. Transfer the separated/isolated cells to a 15 mL conical tube.
Centrifuge the tube at 300 x g for 3-5 minutes to pellet the cells.
Throw the supernatant away and apply 2 mL Mesenchymal Stem Cell Expansion Medium (pre-warmed to 37 °C) containing 8 ng/mL FGF-2 to the conical tube and completely suspend the cells again. Remember not to vortex the cells.
Then, use a hemocytometer to count the number of cells.
Plate the cells at a density of 5,000-6,000 cells per cm2 into the appropriate flasks, plates, or wells in a Mesenchymal Stem Cell Expansion Medium containing 8 ng/mL FGF-2.
Cells can be frozen in MSC growth media plus 10% DMSO (D2650) at a density of 2X106 cells/vial.
Functions of Culture Expanded MSCs
Mesenchymal stem cells are required to be expanded in order for them to be used clinically for therapeutic purposes.
The culture expanded MSCs can be induced to differentiate into adipocytes, osteocytes, hepatocytes, chondrocytes, tenocytes and cardiomyocytes.
Because of its potential to differentiate into different kinds of cells in the body, it can be used to manage liver problems, heart problems, joint and bone problems etc.
Mesenchymal stem cells are also used in tissue regeneration and modulation of the immune system. They possess anti apoptotic, angiogenic, anti fibrotic, and anti-oxidative properties.
However, the quantity of MSCs isolated from body tissues is not enough for clinical and therapeutic applications.
This is why MSCs are expanded in culture to increase their yield for desired therapeutic effect.
- Published in Corporate News / Blog
Why cellular therapies have become a standard in clinics that are betting on biological medicine
Cellular therapy is fast becoming a standard therapy in many regenerative clinics today. Many doctors are no longer questioning the safety and effectiveness of stem cell therapy. This is because various stem cell studies are already describing the benefits of stem cells for patients who are living with chronic and autoimmune health conditions.
This article will be talking about why stem cell therapy have become a standard therapy in clinics, the paracrine effect of stem cells, and other reasons why doctors are adopting stem cells in their clinics.
Benefits of stem cell therapy
Stem cell therapy is an important innovation in medicine because of its regenerative power in the human body. Most disease states are characterized by damaged cells, tissues and organs, which is where stem cell therapy comes in. In stem cell therapy, stem cells are administered into the human body and it replaces the cells damaged by disease or health disorders.
Stem cell research has revealed two major ways of using stem cells to rebuild defective and damaged cells. One of these ways can be seen in procedures like bone marrow transplant, where stem cells are used to replace the damaged cells by engraving, and they then differentiate into the proper cell type. Another mechanism relies on the paracrine effect of stem cells. This procedure of stem cell therapy involves using stem cells isolated from a donor to stimulate the patient’s cells to repair damaged tissues.
Additionally, unlike traditional therapy, stem cells have a wide application. Stem cell therapy is used to manage various degenerative diseases, autoimmune disorders, birth defects, and the research is still ongoing for so many other health conditions where stem cells have shown potential.
Also, there is currently a high demand for aesthetic medicine. Stem cell therapy is a proven alternative to other forms of cosmetology such as plastic surgery. Hence, dermatologists are turning to stem cell therapy to administer anti-aging procedures, skin rejuvenation, hair therapy, micro-needling etc.
The Paracrine effect of stem cells
The paracrine effect of stem cells is one of the most outstanding effects of stem cells. It involves using donor cells to stimulate endogenous repair by harnessing the regenerative power of the human body. It is a mechanism of tissue regeneration that has created new possibilities for managing various conditions using stem cell therapy.
The cells that trigger a paracrine response are; mesenchymal cells, umbilical cord blood, umbilical cord tissue, adipose (fat) tissue and blood cells from a donor’s bone marrow.
The paracrine effect occurs when the donor’s cells send the damaged or defective cells signals to induce self regeneration and repair by secreting some factors and proteins. One of the mechanism by which this paracrine effect is initiated, involves the secretion of cytokines and regulatory proteins by the damaged patient’s cells, these cytokines and proteins act as mediators to stimulate an immune response that attracts the donor cells, this causes the donor cells to release proteins and factors that stimulate the patient’s cells to promote cell proliferation, increase vascularization and blood flow to the areas that needs to heal, while reducing inflammation.
Moreover, research has shown that the paracrine effect of stem cells prevents damaged and diseased cells from dying. They are also therapeutically useful in autoimmune diseases and preventing transplant rejection due to the immune suppression effect they have.
Is stem cell therapy effective?
Doctors are always looking for ways to provide the best possible treatment to their patients, and that is why many clinics are embracing stem cell therapy as a standard, due to its many advantages.
Stem cell therapy is one of the most effective and safest therapy patients can receive, when compared to other existing treatment options. Stem cell therapy is used in promoting patient outcomes in a lot of disease conditions that were previously poorly treated by other alternatives.
Again, as new potentials and ways of applying stem cells are being discovered, doctors are beginning to maximize these benefits in their clinics. Some conditions that are currently treated by stem cells include autoimmune conditions, immunotherapy Car-T cells, chronic obstructive pulmonary disease, neurodegenerative conditions, osteoarthritis, spinal cord injury, aesthetics/anti-aging, sports medicine, autism and multiple sclerosis.
Another reason clinics are adopting stem cell therapy as a standard therapy is because it is easy to administer. A lot of machines such as GCELL {Insert link} which makes the harvesting and processing of stem cells easy and fast, have made the procedures easily adaptable by doctors.
Furthermore, stem cell therapy reduces the treatment and recovery time associated with surgical procedures and other treatment options. This alone is a big factor in why stem cells are becoming a standard therapy in clinics.
Therapeutic uses of stem cells vs traditional medicine
Existing stem cell research has shown how the regenerative effect of stem cells is defining the future of medicine. The major advantage of stem cell therapy over conventional medication-based therapy is its safety. Stem cell therapy is aimed at treating the cause of the disease while traditional medicine targets the symptoms.
Another problem with traditional medical therapy is that it introduces another problem while trying to solve the existing one. As a doctor, you always run the risk of causing harm with each prescription because of various adverse effects that could lead to major organ damage of the kidney, liver etc. On the other hand, patients already know this and they are actively seeking better alternatives, this is why stem cell therapy is fast becoming a standard therapy in clinics.
Moreover, doctors will always be concerned about whether their patients are taking their medications or not. The burden of drug compliance and adherence associated with traditional medical therapy is not always easy to navigate. This is why effective treatment options like stem cell therapy have become a standard therapy in clinics. It only requires the patients having a procedure that repairs and restores damaged cells and tissues in the most natural way.
If you would like to become certified in regenerative medicine using stem cells and other cellular therapy, contact us.
- Published in Corporate News / Blog
Meso Numismatics Closes Global Stem Cell Group Acquisition
LAS VEGAS, NV, August 18, 2021 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Meso Numismatics, Inc. (“Meso Numismatics” or the “Company”) (MSSV), a technology and numismatic company specializing in the Meso Region, including Central America and the Caribbean, MSSV is pleased to announce that it has closed its acquisition of Global Stem Cells Group. “We are pleased to have finally been able to close on this acquisition,” said David Christensen, President and CEO of MSSV,” We are now well positioned to enter into the growing global Regenerative Medicine industry.”
Global Stem Cells Group (Global) is a premier Regenerative Medicine company that specializes in cutting edge stem cell research, current clinical applications, and physician training. Global licenses its intellectual property and name to medical professionals around the world providing them with necessary equipment and cellular therapy products needed to perform safe and effective Regenerative medicine related treatments. Global has one of the larges physician membership networks in the world with 29 offices in more than 25 countries. The worldwide Regenerative Medicine industry is a multi billion-dollar industry projected to have double digit annual growth rates over the next decade. For more information on Global Stem Cells Group please follow the link www.stemcellsgroup.com
Please read this press release in conjunction with the 8K that was filed today on www.sec.gov.
MSSV has also renegotiated its June 22, 2021 $10.5M financing, of which $8.2M is earmarked for the Lans Holdings Escrow as per the 8k filed June 24th, 2021, as follows: the warrant maturity has been changed to 7 years instead of 3 years and the warrant shall be locked up for the first 2 years whereas during the lock up period the warrant will not be able to be exercised.
This press release should be read in conjunction with all other filings on www.sec.gov
For more information on Global Stem Cells Group please visit: www.stemcellsgroup.com
About Meso Numismatics: Meso Numismatics, Corp is an emerging numismatic and technology company specialized in the Meso Region, including Central America and the Caribbean. The Company has quickly become the central hub for rare, exquisite, and valuable inventory for not only the Meso region, but for exceptional items from around the world. With the Company’s breadth of business experience and technology team, the Company will continue to help companies grow. Meso has now added bio-technology to it’s portfolio and will continue to grow the company in this new direction.
This press release should be read in conjunction with all other filings on www.sec.gov
For more information on Global Stem Cells Group please visit: www.stemcellsgroup.com
About Meso Numismatics: Meso Numismatics, Corp is an emerging numismatic and technology company specialized in the Meso Region, including Central America and the Caribbean. The Company has quickly become the central hub for rare, exquisite, and valuable inventory for not only the Meso region, but for exceptional items from around the world. With the Company’s breadth of business experience and technology team, the Company will continue to help companies grow.
Forward Looking Statements
Some information in this document constitutes forward-looking statements or statements which may be deemed or construed to be forward-looking statements, such as the closing of the share exchange agreement. The words “plan”, “forecast”, “anticipates”, “estimate”, “project”, “intend”, “expect”, “should”, “believe”, and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause the Company’s actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in the Company’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Meso Numismatics, Inc., herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Meso Numismatics, Inc. disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.
For further information, please contact:
Investor.relations@mssvinc.com
Telephone: (800) 956-3935
- Published in Press Releases
ISSCA to Host 6th Annual Regenerative Medicine Symposium in Buenos Aires, Argentina Aug. 16-17, 2019
ISSCA’s 2019 “Applications of Cell Therapies in Medicine and Aesthetic Surgery” symposium agenda to focus on allogeneic compounds in the regenerative medicine industry.
MIAMI, Dec. 18, 2018—The International Association for Stem Cell Application (ISSCA) has announced plans to host its sixth annual “Applications of Cell Therapies in Medicine and Aesthetic Surgery” regenerative medicine symposium in Buenos Aires, Argentina August 16-17, 2019. The focus of the symposium agenda will be allogeneic compounds—how they have changed the regenerative medicine industry, and how the industry will accommodate the challenges allogeneic therapies present.
The international symposium is part of ISSCA’s mission to support a paradigm shift in healthcare from traditional to regenerative medicine in the 21st Century and provide cutting-edge information on developments in all areas of stem cell research.
In 2018, the 5th annual symposium was held in three international cities—Buenos Aires, Istanbul, Turkey and Caracas, Venezuela. Each event exceeded organizers’ expectations both in attendance numbers and active participation. More than 200 physicians from the U.S., South America, Europe, the Middle East and Asia attended the symposiums in Istanbul and Caracas, and more than 350 physicians from around the world attended in Buenos Aires.
The high attendance and enthusiastic participation of attendees at the Argentina symposium, which was held at the Universidad de Buenos Aires, compelled ISSCA organizers to reconsider their multi-country strategy and host the event exclusively in Buenos Aires in 2019. In addition, ISSCA has committed to hosting the annual symposium in Buenos Aires for the next six consecutive years.
In keeping with ISSCA’s commitment to supporting the most current advances in stem cell and regenerative medicine discoveries, the 2019 symposium will explore the impact the acceleration of allogeneic compounds have had on the industry, new challenges they bring to the market, and promising new therapies they are expected to provide to an ever-widening spectrum of diseases and medical conditions.
A group of renowned international speakers, experts in the field of stem cell and regenerative medicine including the latest advances in allogeneic therapies, will lead rigorous scientific discussions and Q&A sessions with physicians in attendance. In Addition, ISSCA has invited representatives from [name of’ lab?], one of the world’s largest regenerative medicine labs to share their experiences and knowledge with physicians representing the global medical community in attendance,
The symposium will incorporate the biology, medicine, applications, regulations, product development, and commercialization of stem cells and regenerative medicine solutions.. In addition, business opportunities, industry challenges, and potential strategies for overcoming those challenges will be discussed.
The event venue in Buenos Aires will be announced shortly.
To learn more about the ISSCA Buenos Aires symposium and to reserve a seat, visit the stemcellconference.org website, email info@stemcellsgroup.com, or call +1305 560 5337.
About ISSCA:
The International Society for Stem Cell Application (ISSCA) is a multidisciplinary community of scientists and physicians, all of whom aspire to treat diseases and lessen human suffering through advances in science, technology and the practice of regenerative medicine. ISSCA serves its members through advancements made to the specialty of regenerative medicine.
The ISSCA’s vision is to take a leadership position in promoting excellence and setting standards in the regenerative medicine fields of publication, research, education, training. and certification.
As a medical specialty, regenerative medicine standards and certifications are essential, which is why ISSCA offers certification training in cities all over the world. The goal is to encourage more physicians to practice regenerative medicine and make it available to benefit patients both nationally and globally. Incorporated under the Republic of Korea as a non-profit entity, the ISSCA is focused on promoting excellence and standards in the field of regenerative medicine.
###
Regenerative medicine symposium allogeneic compounds
- Published in Press Releases
ISSCA announces the 2019 Regenerative Medicine Certification Calendar
ISSCA has released its 2019 regenerative medicine training calendar for physicians, to be held in seven international cities.
MIAMI, Dec. 4, 2018—The International Society for Stem Cell Application (ISSCA) has released its 2019 regenerative medicine certification training course calendar, with programs scheduled in seven international cities and updated curriculum. ISSCA’s objective in 2019 is to provide enhanced educational qualifications to physicians looking for a new approach to treat patients suffering with chronic pain, severe injury, and degenerative conditions and diseases.
The two-day regenerative medicine training course, which teaches easy-to-follow protocols for harvesting adipose and bone marrow stem cells from patients in a clinical environment, will also feature new treatment basics involving allogeneic compounds including exosomes and other compounds derived from (umbilical) cord blood and amniotic fluid, allowing participating physicians to easily and efficiently add certification in cutting-edge regenerative medicine therapies to their practices.
Participating physicians learn how to harvest and isolate bone marrow and adipose-derived autologous stem cells to use in treating multiple conditions.
The two-day course begins with a four-hour lecture on advances in regenerative medicine. Participating physicians will receive more than 12 hours of hands-on training with live patients in protocols for obtaining stem cells from patients, applications that they can take back to their medical offices or clinics and begin using immediately.
Attendees will also receive 12 protocols in digital format to take with them, and gain knowledge and practical skills to easily add regenerative medicine therapies to their practices.
Physicians will also receive access to the online stem cell training course to review all content and procedures introduced in the 2-day clinical training course, patient forms and guidelines, procedure informed consent forms, didactic lectures, training booklets and more.
The 2019 ISSCA training course calendar is as follows:
January 18-19, 2019 Miami, Fla. (conducted in Spanish language).
http://cursocelulasmadre.com/entrenamiento-miami-mail/ January 25.26, 2019 Miami, Fla. (Conducted in English language). https://www.stemcelltraining.net/miami-stem-cells-course-adwords/
February 1-2, 2019 Quito, Ecuador
http://cursocelulasmadre.com/entrenamiento-quito-mail/
February 8-9, 2019 Buenos Aires, Argentina
https://cursocelulasmadre.com/entrenamiento-argentina-mail/
February 15-16, 2019, Lima, Peru
http://cursocelulasmadre.com/entrenamiento-lima-mail/
Fenruary 22-23, 2019 Bogota, Colombia
http://cursocelulasmadre.com/entrenamiento-bogota-mail/
March 1-2, 2019 Mexico City, Mexico
https://cursocelulasmadre.com/entrenamiento-cancun-mail/ – needs to be fixed – links to a December date!
March 8-9 Abu Dabhi, UAE
https://www.stemcelltraining.net – not a good link! Please correct
ISSA’s stem cell certification course offers practical, personalized training in stem cell harvesting and isolation procedures. To date, ISSCA has trained more than 2,000 physicians worldwide.
Stem cell therapies continue to revolutionize the healthcare industry and help improve the quality of life for patients.
To learn more about the ISSCA certification training courses and to register to participate, visit the Stem Cells Training website, the email info@stemcellsgroup.com, or call 305-560-5337.
About ISSCA:
The International Society for Stem Cell Application (ISSCA) is a multidisciplinary community of scientists and physicians, all of whom aspire to treat diseases and lessen human suffering through advances in science, technology and the practice of regenerative medicine. ISSCA serves its members through advancements made to the specialty of regenerative medicine.
The ISSCA’s vision is to take a leadership position in promoting excellence and setting standards in the regenerative medicine fields of publication, research, education, training, and certification.
As a medical specialty, regenerative medicine standards and certifications are essential, which is why ISSCA offers certification training in cities all over the world. The goal is to encourage more physicians to practice regenerative medicine and make it available to benefit patients both nationally and globally. Incorporated under the Republic of Korea as a non-profit entity, the ISSCA is focused on promoting excellence and standards in the field of regenerative medicine.
###
ISSCA 2019 certification training calendar
- Published in Press Releases
ISSCA to Conduct Sponsored Regenerative Medicine Training Course in Caracas, Venezuela Dec. 2-3, 2018
ISSCA will conduct a hands-on regenerative medicine certification training course for physicians in Caracas, Venezuela Dec. 2-3, 2018. Global Stem Cells Group will sponsor 50 percent of the training fees to provide most physicians in economically-strapped Venezuela with access to regenerative medicine education.
MIAMI, Nov. 1, 2018—The International Society for Stem Cell Application (ISSCA) announces plans to hold a regenerative medicine certification training course in Caracas, Venezuela Dec. 2-3, 2018. The two-day course teaches easy-to-follow protocols for harvesting adipose and bone marrow stem cells from patients in a clinical environment..
The training program follows the organization’s sponsored regenerative medicine symposium in Caracas on Dec. 1, 2018. ISSCA affiliate Global Stem Cells Group Group is sponsoring the training program and funding 50 percent of fee costs to ensure most Venezuelan physicians can attend.
GSCG CEO and ISSCA Vice President Benito Novas says the training program is an important part of the organizations’ commitment to spreading knowledge and physician training in regenerative medicine to medical professionals worldwide. This commitment includes strategies to accommodate countries like Venezuela that lack the resources to train physicians to implement regenerative medicine procedures in clinical settings.
“Our goal is to make economically and therapeutically viable regenerative medicine therapies available to Venezuelans by training and educating physicians throughout the country in stem cell therapies and protocols they can provide to patients in their clinics, says Novas. “We’re driven by our conviction that stem cell medicine will bring transformative changes to the healthcare industry at a global level.
Participating physicians learn how to harvest and isolate bone marrow and adipose-derived autologous stem cells to use in treating multiple conditions.
The two-day course begins with a four hour lecture on advances in regenerative medicine. Participating physicians will receive more than 12 hours of hands-on training with live patients in protocols for obtaining stem cells from patients that can be used in the medical office. They will also receive 12 protocols in digital format to take back to their practices and begin using stem cell applications immediately.
The course provides participating physicians with training in stem cell therapies to treat a variety of conditions. Participating physicians gain Knowledge and practical skills to easily add regenerative medicine to their practices.
Physicians will also receive access to the online stem cell training course to review all content and procedures introduced in the 2-day clinical training course, patient forms and guidelines, procedure informed consent forms, didactic lectures, training booklets and more.
ISSCA’s stem cell certification course offers practical, personalized training in stem cell harvesting and isolation..ISSCA has trained more than 2,000 physicians worldwide.
Stem cell therapies continue to revolutionize the healthcare industry and help improve the quality of life for patients.
To learn more about the ISSCA certification training course and to register to participate, visit the Stem Cells Training website, the email info@stemcellsgroup.com, or call 305-560-5337.
About ISSCA:
The International Society for Stem Cell Application (ISSCA) is a multidisciplinary community of scientists and physicians, all of whom aspire to treat diseases and lessen human suffering through advances in science, technology and the practice of regenerative medicine. ISSCA serves its members through advancements made to the specialty of regenerative medicine.
The ISSCA’s vision is to take a leadership position in promoting excellence and setting standards in the regenerative medicine fields of publication, research, education, training, and certification.
As a medical specialty, regenerative medicine standards and certifications are essential, which is why ISSCA offers certification training in cities all over the world. The goal is to encourage more physicians to practice regenerative medicine and make it available to benefit patients both nationally and globally. Incorporated under the Republic of Korea as a non-profit entity, the ISSCA is focused on promoting excellence and standards in the field of regenerative medicine.
About Global Stem Cells Group:
Global Stem Cells Group (GSCG) is a worldwide network that combines seven major medical corporations. Each corporation is focused on furthering scientific and technological advancements in cutting-edge stem cell research, development, treatment, and training. The united efforts of GSCG’s affiliate companies provide medical practitioners with a one-stop epicenter for stem cell solutions that adhere to the highest medical standards.
Global stem cell’s mission is to be the largest recognized stem cell and regenerative medicine network in the world. About Adimarket: Adimarket, Inc., a division of the Global Stem Cells Group, is a one-stop, cost-competitive online marketplace for quality regenerative medicine equipment and supplies for physicians and healthcare professionals.
###
Caracas Venezuela stem cell training
- Published in Press Releases
Global Stem Cells Group Announces New Business Development Director for Africa and Europe
Global Stem Cells Group announces the appointment of Holya Aziza El Materi Ep Khemiri, M.D. as Vice President Business Development Africa and Europe. Khemiri will oversee development of a new Stem Cell Center in Tunisia.
MIAMI, Nov. 1, 2018—Global Stem Cells Group founder and CEO Benito Novas has named Holya Aziza El Materi Ep Khemiri, M.D. Vice President Business Development for Africa and Europe. The announcement is the latest update on the regenerative medicine organization’s expansion of its clinical presence on the two continents.
Khemiri, who specializes in pharmaceutical and parapharmacy medicines, product manufacturing and medical industry business development, will be in charge of developing and opening a new Stem Cell Center in Tunisia focused on the treatment of patients with degenerative illnesses and orthopedic impairments, and professional athletes with sports injuries.
Stem Cell Center Tunisia will provide regenerative medicine training to African physicians who wish to offer stem cell therapies in their practices.
Since opening the first African Stem Cell Center in Casablanca, Morocco in July, 2017, GSCG has accelerated momentum to bring regenerative medicine, training and education to Africa and Europe through expanded networking opportunities introducing the organization’s authoritative training programs, workshops, seminars, online marketplace for regenerative medicine products, expert instruction and advice on marketing for regenerative practices and other innovative initiatives.
Stem Cell Center Tunisia is part of Global Stem Cells Group’s strategy to facilitate international growth and bring quality-of-life-enhancing regenerative medicine to patients in every corner of the world. The Tunisian center’s medical team will work closely with regional patients, educators and regulators to foster engagement and promote stem cell medicine technology.
ction as a regenerative medicine reference for physicians in North Africa, providing physicians with instruction in stem cell therapies and protocols Those wishing to implement stem cell oversight in their practices will be able to visit the office and collaborate other physicians, participate in educational classes and workshops, and receive the training necessary to start implementing regenerative medicine in their practices and clinics.
Additionally, Stem Cell Center Tunisia will offer physicians a stem cell processing center, GSCG’s complete solution for onsite tissue processing, isolation, culturing and cryopreservation of stem cells. One of the biggest challenges of using traditional stem cell harvesting protocols in medical office settings is obtaining enough stem cells to treat certain degenerative conditions such as autism, lupus. Parkinson’s Disease, Alzheimer’s Disease and others.
The stem cell processing center provides a solution that allows physicians to expand stem cell colonies and obtain a significantly larger number of cells sufficient to treat patients. It also helps with patients needing multiple stem cell treatments by allowing the physician to perform a single extraction of stem cells from fat tissue; the cells harvested can then be saved and expanded, eliminating the need for new cell extraction with each treatment.
According to Novas, Khemiri’s skills and experience make her an ideal candidate to spearhead Stem Cell Center Tunisia’s development and opening.
“Dr. Khemiri brings an array of expertise and knowledge to our expansion efforts in Africa and Europe,” says Novas. She joins Global Stem Cells Group’s management team as a welcome addition at a time when our international expansion endeavors are growing exponentially.”
Khemiri was president of Tunisia’s Society Isotope Radioavtive (SISORA) from 2011 to 2014, where she was involved in manufacturing radioactive tracers to detect cancer. As president of the organization, she helped establish a partnership between SISORA and Belgium-based Radio Pharma Solultions (IBA).
From 2008 to 2011, she served as Research and Development Director of ADWYA, a Tunisia-based company specializing in the production of pharmaceutical products for medical and veterinary use and the country’s first private pharmaceutical laboratory and one of its largest private pharmaceutical companies.
In 2010, she served as creative director of RAD where she focused on formula and scientific studies and registration of medicines, skin care and food supplements with the Tunisian Health Ministry.
Khemari received her medical training at the Catholic University of Louvain in Brussels, Belgium from 1999 to 2006. She received a diploma in Pharmaceutical Sciences from the the Institut Roger Lambion in Brussels and a diploma in Biochemistry, Cosmetology, and Science Perfumery from the University Libre in Brussels.
For more information, visit the Global Stem Cells Group website, email info@stemcellsgroup.com or call 305-560-5337.
About Global Stem Cells Group:
Global Stem Cells Group (GSCG) is a worldwide network that combines seven major medical corporations. Each corporation is focused on furthering scientific and technological advancements in cutting-edge stem cell research, development, treatment, and training. The united efforts of GSCG’s affiliate companies provide medical practitioners with a one-stop epicenter for stem cell solutions that adhere to the highest medical standards.
Global stem cell’s mission is to be the largest recognized stem cell and regenerative medicine network in the world. About Adimarket: Adimarket, Inc., a division of the Global Stem Cells Group, is a one-stop, cost-competitive online marketplace for quality regenerative medicine equipment and supplies for physicians and healthcare professionals.
###
Holya Aziza El Materi Ep Khemiri named Vice President Business Development Africa and Europe.
- Published in Press Releases
ISSCA to Host Sponsored Regenerative Medicine Symposium in Caracas, Venezuela Dec. 1, 2018
ISSCA announce plans to host the World Symposium on Regenerative Medicine and Cell Therapies in Venezuela Dec. 1, 2018, Event organizers will sponsor 50 percent of event fees to provide most physicians in economically-strapped Venezuela with access to regenerative medicine education.
MIAMI, Sept. 28 2018—International Society for Stem Cell Application (ISSCA), in keeping with its mission to promote regenerative medicine in clinical applications and provide clinical stem cell therapy training to physicians worldwide, announces plans to host the World Symposium on Regenerative Medicine and Cell Therapies: “Adult Stem Cells. The immediate future of Medicine” in Caracas, Venezuela December 1, 2018.
Global Stem Cells Group (GSCG) CEO and ISSCA Vice President Benito Novas says the symposium is an important event for both organizations’ commitment to spreading knowledge and physician training in regenerative medicine to medical professionals worldwide. This commitment includes strategies to accommodate countries like Venezuela that lack the resources to train physicians to implement regenerative medicine procedures in clinical settings.
“Global Stem Cells Group understands the difficult financial conditions that are depriving Venezuelans of essential advances in medicine including cellular therapies that are being used to improve the quality of life for patients in countries around the world,” says Novas. “GSCG is committed to providing regenerative medicine training and education to physicians everywhere.”
According to Novas, the dire state of Venezuela ‘s health care system is a call-to-action for ISSCA and Global Stem Cells Group Group is sponsoring the event and funding 50 percent of event fee costs to ensure most Venezuelan physicians can attend.
The goal is to make economically and therapeutically viable regenerative medicine therapies available to Venezuelans by training and educating physicians throughout the country in stem cell therapies and protocols they can provide to patients in their clinics.
“The opportunity to sponsor this important symposium is very gratifying to us, as it resonates with GSCG’s core mission to bring regenerative medicine to countries around the world,” Novas says. “We’re driven by our conviction that stem cell medicine will bring transformative changes to the healthcare industry at a global level.
“Regenerative cellular therapies are already replacing invasive treatment practices and improving quality of life outcomes for patients suffering from illnesses and injuries that are not treatable with traditional medicine, he says. “Global Stem Cells Group is motivated to take this first step toward making economically and therapeutically viable regenerative medicine therapies available to Venezuelans.
“This symposium is an important step toward making regenerative medicine education and training available to physicians in Venezuela.”
Symposium topics of focus include:
- Clinical applications for regenerative medicine to treat sports injuries
- Stem cell procedures to treat erectile dysfunction
- How mesenchymal stem cells contribute to renal repair in the treatment of acute tubular epithelial injury
- Management of aging at the cellular level
- Managing advanced aging with combined treatment plans that include surgical procedures
- Restoration and assisted hair transplantation treatments with biomaterials and growth factors
More than 16 experts in the field of regenerative medicine will be featured speakers at the event, including:
- Silvina Pastrana, Medical Director of Stem Cells Center Buenos Aires (Argentina), who will discuss stem cell therapy fundamentals and protocols in the medical office
- Jose Benitez, M.D., Medical Director of Boston Médical Group (Spain), whose lecture will focus on the most recent successful regenerative medicine clinical trial for treating erectile diffusion.
The World Symposium on Regenerative Medicine and Cell Therapies will be held Dec. 1, 2018 at the Marriott Hotel in Caracas, Venezuela. For more information and registration, visit the symposium website, email info@stemcellsgroup.com, or call +1305 560 5337.|
About ISSCA:
The International Society for Stem Cell Application (ISSCA) is a multidisciplinary community of scientists and physicians, all of whom aspire to treat diseases and lessen human suffering through advances in science, technology and the practice of regenerative medicine.
ISSCA serves its members through advancements made in the specialty of regenerative medicine.ISSCA’s vision is to take a leadership position in promoting excellence and setting standards in the regenerative medicine fields of publication, research, education, training, and certification.
As a medical specialty, regenerative medicine standards and certifications are essential, which is why ISSCA offers certification training in cities all over the world. The goal is to encourage more physicians to practice regenerative medicine and make it available to benefit patients both nationally and globally. Incorporated under the Republic of Korea as a non-profit entity, the ISSCA is focused on promoting excellence and standards in the field of regenerative medicine.
About Global Stem Cells Group:
Global Stem Cells Group (GSCG) is a worldwide network that combines seven major medical corporations. Each corporation is focused on furthering scientific and technological advancements in cutting-edge stem cell research, development, treatment, and training. The united efforts of GSCG’s affiliate companies provide medical practitioners with an online, one-stop center for stem cell solutions that adhere to the highest medical standards.
Regenerative medicine symposium e Caracus Venezuela
- Published in Press Releases
Global Stem Cells Group launches “Regenerative Medicine” video blog on YouTube
Global Stem Cells Group announces the launch of the new “Regenerative Medicine” vlog featuring interviews with leaders in regenerative medicine.
MIAMI, Sept. 14, 2018–Global Stem Cells Group (GSCG), a word leader in regenerative medicine, has launched a new video blog (vlog) titled “Regenerative Medicine” on its YouTube channel. Physicians who incorporate regenerative medicine therapies in their patient treatments are invited to participate in the vlog.
The idea is to create a space for regenerative medicine practitioners to share their clinical experiences with viewers around the world. New interviews will be recorded and aired weekly on the “Regenerative Medicine” vlog.
The new vlog channel is part of Global Stem Cells Group’s ongoing effort to spread the word about the benefits of regenerative medicine therapies to viewers around the world and to provide practitioners with an opportunity to discuss their regenerative medicine practices with interested audiences, and stay abreast of what other practitioners in the field are doing.
According to Benito Novas, GSCG CEO, the vlog platform will provide an additional point of reference for physicians and patients looking for the latest information on stem cell research and therapies. It is also designed to help clarify the scope of stem cell procedures and to dispel myths and false information among audiences. All physicians who wish to participate in GSCG’s new vlog program will be included and encouraged to speak freely.
Physicians wishing to participate in an interview for the GSCG “Regenerative Medicine” vlog series are asked to email their CV and abstract to info@stemcellsgroup,com.
The Regenerative Medicine vlog will be posted on Global Stem Cells Group’s YouTube Channel and physician interviews will also be posted on the News ABout Cell Therapies blog.
For more information about Global Stem Cells Group, visit the GSCG website, email: info@stemcellsgroup.com, or call +1305 560 5337.
About Global Stem Cells Group:
Global Stem Cells Group (GSCG) is a worldwide network that combines seven major medical corporations. Each corporation is focused on furthering scientific and technological advancements in cutting-edge stem cell research, development, treatment, and training. The united efforts of GSCG’s affiliate companies provide medical practitioners with a one-stop epicenter for stem cell solutions that adhere to the highest medical standards.
Global stem cell’s mission is to be the largest recognized stem cell and regenerative medicine network in the world
- Published in Press Releases